- Home
- PRME vs DOUG Comparison
PRME vs DOUG Comparison
Compare PRME & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRME
- DOUG
- Stock Information
- Founded
- PRME 2019
- DOUG 1911
- Country
- PRME United States
- DOUG United States
- Employees
- PRME N/A
- DOUG N/A
- Industry
- PRME Medicinal Chemicals and Botanical Products
- DOUG Building operators
- Sector
- PRME Health Care
- DOUG Real Estate
- Exchange
- PRME Nasdaq
- DOUG Nasdaq
- Market Cap
- PRME 191.7M
- DOUG 161.5M
- IPO Year
- PRME 2022
- DOUG N/A
- Fundamental
- Price
- PRME $4.21
- DOUG $3.03
- Analyst Decision
- PRME Buy
- DOUG
- Analyst Count
- PRME 6
- DOUG 0
- Target Price
- PRME $9.38
- DOUG N/A
- AVG Volume (30 Days)
- PRME 5.8M
- DOUG 1.0M
- Earning Date
- PRME 08-08-2025
- DOUG 08-01-2025
- Dividend Yield
- PRME N/A
- DOUG N/A
- EPS Growth
- PRME N/A
- DOUG N/A
- EPS
- PRME N/A
- DOUG N/A
- Revenue
- PRME $3,846,000.00
- DOUG $1,048,791,000.00
- Revenue This Year
- PRME $104.12
- DOUG $17.61
- Revenue Next Year
- PRME $108.24
- DOUG N/A
- P/E Ratio
- PRME N/A
- DOUG N/A
- Revenue Growth
- PRME 550.76
- DOUG 11.36
- 52 Week Low
- PRME $1.11
- DOUG $1.28
- 52 Week High
- PRME $5.95
- DOUG $3.20
- Technical
- Relative Strength Index (RSI)
- PRME 60.42
- DOUG 74.53
- Support Level
- PRME $3.71
- DOUG $2.70
- Resistance Level
- PRME $5.15
- DOUG $2.82
- Average True Range (ATR)
- PRME 0.53
- DOUG 0.12
- MACD
- PRME -0.06
- DOUG 0.05
- Stochastic Oscillator
- PRME 34.25
- DOUG 99.25
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.